Indication

As monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy

Medicine details

Medicine name:
avelumab (Bavencio)
SMC ID:
SMC2359
Pharmaceutical company
Merck
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
09 August 2021
SMC meeting date:
06 July 2021
Patient group submission deadline:
03 May 2021